Core Viewpoint - The article discusses Sam Altman's increased investment in the biotech startup Retro Biosciences, which aims to extend human lifespan by 10 years through innovative therapies targeting aging and related diseases [3][4][33]. Investment and Company Overview - Sam Altman has invested a total of $180 million (approximately 1.3 billion RMB) in Retro Biosciences, indicating strong support for the company's mission [4]. - Retro Biosciences plans to initiate its first human clinical trial for an experimental drug, RTR242, by the end of 2025 [8][12]. - The company has previously collaborated with OpenAI to develop a model called GPT-4b-micro, designed for protein engineering [5][28]. Scientific Approach and Mechanism - RTR242 aims to enhance the cellular "garbage disposal and recycling system" to clear damaged cellular components, potentially reversing aging effects [16]. - The drug targets "cellular garbage" associated with Alzheimer's and Parkinson's diseases, aiming to restart the autophagy process in aging individuals [17]. - Retro is also developing therapies for leukemia and central nervous system diseases, indicating a broad approach to longevity [34]. Future Goals and Funding - Retro Biosciences has set an ambitious goal to increase healthy human lifespan by 10 years, focusing on maintaining health and vitality until the end of life [33]. - The company aims to raise $1 billion in its Series A funding round to support its clinical trials and research initiatives [35]. - Comparatively, other longevity companies like Altos Labs have raised over $3 billion, highlighting the competitive landscape in the longevity biotech sector [37]. Leadership and Expertise - The CEO of Retro Biosciences, Bates-Lacroix, has a strong background in protein research and has previously led successful ventures in the tech industry [44]. - The company also features a co-founder, Ding Sheng, known for his expertise in stem cell research, enhancing the company's scientific credibility [41].